drugset / Trial / NCT05577624

A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

NCT05577624

Phase 1 Completed 14 enrolled Amgen
NaSingle-groupOpen-labelBasic science

Summary

The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.

Timeline

Start
2019-11-05
Primary completion
2019-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule Oral
Subject Sotorasib Small molecule Oral

Indications

No indication recorded.